NCT04457089CompletedEarly phase 1
Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This is a single arm pilot trial to evaluate the feasibility of using a simvastatin intervention, and to evaluate its effects on cancer progression, among 20 patients with platinum-sensitive ovarian cancer, treated with carboplatin and liposomal doxorubicin at Cedars-Sinai Medical Center.
- Status (registry)
- Completed
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 25 Jun 2020
- Start date
- 25 Jan 2021
- Primary completion date
- 1 Nov 2024
- Lead sponsor
- Marc Goodman
- Diseases
- Ovarian cancer
- NCT number
- NCT04457089
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 18
- From 25 Jan 2021 to the primary completion date, 1 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior or current use of any statin medication
- Current systemic use of medications known to interact with statins
- Current use of any other investigational agents
- Prior exposure to doxorubicin or liposomal doxorubicin
Other illness
- Liver disease, active cirrhosis
- Uncontrolled intercurrent illness
- History of chronic myopathy
- Prior cancer other than ovarian cancer or non-melanomatous skin cancers
- Known active infection with HIV
Lab values
- Hemoglobin A1C \>8.0%
Other
- Current excessive alcohol consumption (average alcohol consumption of more than 5 drinks per day)
Who the study is looking for
- Recurrent platinum sensitive ovarian cancer, all histologies (serous, endometrioid, mucinous, clear cell). Platinum sensitivity defined as ≥ 6 months since last platinum treatment.
- No contraindication to carboplatin and/or liposomal doxorubicin or simvastatin.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.